Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και Εκτέλεση
Library of the School of Health Sciences

2019-06-21

2019

Karamanis Alexandros

Καστρίτης Ευστάθιος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών.
Ζαγουρή Φλώρα, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών.
Γαβριατοπούλου Μαρία, Επίκουρη Καθηγήτρια, Ιατρική Σχολή, Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών.

Brigatinib overview: A next generation ALK inhibitor for advance ALK positive NSCLC

Greek

Brigatinib overview: A next generation ALK inhibitor for advance ALK positive NSCLC

Lung cancer is the most common and lethal type of cancer worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. 2-7% of patients with NSCLC are positive for ALK gene rearrangements and often develope resistance to treatment with inhibitors. The most commonly administered ALK inhibitors to patients with ALK-positive NSCLC are crizotinib, ceritinib and alectinib. Brigatinib is considered a promising drug as it exhibits activity when other ALK inhibitors are not effective. Brigatinib's action is based on inhibition of phosphate binding in ALK, resulting in the inhibition of phosphorylation of other proteins involved in the pathogenesis of lung cancer.
In this work, a review was performed in the Pubmed database, and according to the PRISMA guidelines, out of the 113 records, we reached 4. One of the entries concerned a preclinical trial and the other three, Phase I, II and III clinical trials.
The results of the preclinical study in cell lines and mouse models showed stronger brigatinib activity in both wild type ALK and ALK with secondary resistance mutations compared to crizotinib. Phase I and II clinical studies revealed that brigatinib administration in patients treated with brigatinib at a dose of 90 and 180 mg once daily resulted in an objective response of 45-54%, progression-free survival of 9.2-12.9 months and median intracranial progression-free survival of 12.8-15.6 months. Finally, in the Phase III clinical trial, the results showed that brigatinib, compared with crizotinib, was associated with a 51% lower risk of disease progression or death, an objective response rate of 71% and an intracranial objective response rate of 83%.
The above studies have clearly demonstrated the benefit of brigatinib administration in patients with ALK-positive NSCLC previous treated with crizotinib.

Health Sciences

Brigatinib, Non-small cell lung cancer, Anaplastic lymphoma kinase inhibitor, Thyrosine kinase inhibitor, Metastatic non-small cell lung cancer

No

0

Yes

117

78

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2876478